S-1: PMGC Holdings Files S-1 for Resale, Secures $20M Equity Line

PMGC Holdings Inc. filed an S-1 registration statement for the resale of up to 5 million common shares by Streeterville Capital, LLC, following a new $20 million equity line of credit and recent strategic acquisitions.

Summary

• PMGC Holdings Inc. has filed a Registration Statement on Form S-1 for the resale of up to 5,000,000 shares of common stock by Streeterville Capital, LLC.
• The shares include 56,700 commitment shares and 10,300 pre-delivery shares issued to Streeterville Capital, LLC, on September 26, 2025, as part of an initial $5,000,000 pre-paid purchase.
• An equity line of credit with Streeterville Capital, LLC, provides for up to $20,000,000 in aggregate purchase amount, with net proceeds of $3,990,000 received from the initial pre-paid purchase.
• The company completed the divestiture of its Elevai Skincare Inc. business on January 16, 2025, to focus on biotechnology and diversified investments.
• PMGC Holdings now operates five wholly-owned subsidiaries: Northstrive Biosciences Inc. (biopharmaceutical), PMGC Research Inc. (R&D), PMGC Capital LLC (investment firm), Pacific Sun Packaging, Inc. (specialty packaging), and AGA Precision Systems LLC (CNC machine shop).
• Northstrive Biosciences is advancing EL-22, an engineered probiotic for muscle preservation during weight loss treatments (including GLP-1 receptor agonists), which completed a Phase 1 clinical trial in South Korea with promising safety results.
• The company acquired 100% of Pacific Sun Packaging Inc. on July 7, 2025, for $1,148,000 in cash and a potential earnout of up to $250,000.
• The company acquired 100% of AGA Precision Systems LLC on July 18, 2025, for $650,000 in cash.
• PMGC Holdings reported a net working capital of $6,976,543 as of June 30, 2025, and an accumulated deficit of $15,440,437.
• Net loss from continuing operations for the six months ended June 30, 2025, was $2,160,301, compared to $1,097,032 for the same period in 2024.
• The company effected a 3.5-for-1 reverse stock split on September 2, 2025, and increased authorized common stock to 2,000,000,000 shares on September 15, 2025.
• Voting control is concentrated, with Northstrive Companies Inc. (wholly owned by Chairman Braeden Lichti) and GB Capital Ltd (wholly owned by CEO Graydon Bensler) collectively holding approximately 81.11% of the company's voting capital stock.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, evidenced by recurring losses, a substantial accumulated deficit, and explicit 'going concern' doubt. While recent capital raises and strategic shifts are positive, the underlying financial health remains precarious, and the long-term success of its biotechnology assets is highly uncertain and capital-intensive.

Positives

• Secured an equity line of credit for up to $20,000,000 with Streeterville Capital, LLC, providing access to capital.
• Successfully divested the skincare business to focus on higher-growth biotechnology and diversified investment opportunities.
• Northstrive Biosciences' lead asset, EL-22, completed a Phase 1 clinical trial in South Korea, showing promising safety and tolerability.
• Acquired two operating companies, Pacific Sun Packaging Inc. and AGA Precision Systems LLC, diversifying the portfolio into specialty packaging and precision machining.
• Increased cash position to $5,682,628 as of June 30, 2025, from $3,984,453 at December 31, 2024.
• Net working capital improved to $6,976,543 as of June 30, 2025, from $4,251,867 at December 31, 2024.
• Received gross proceeds of $1,668,218.50 from warrant inducement transactions in August 2025.
• Received net proceeds of approximately $1,245,305.76 from a registered direct offering in March 2025.
• Received $1,938,772 from the exercise of Series A Warrants in January 2025.
• Northstrive Biosciences expanded its license agreement for EL-22 to include animal health applications, including feed additives, in March 2025.
• The company has a comprehensive intellectual property portfolio, including registered domain names and multiple patent applications for its biotechnology assets.

Negatives

• The company's financial statements have been prepared on a going-concern basis, indicating substantial doubt about its ability to continue operations.
• Reported an accumulated deficit of $15,440,437 as of June 30, 2025, and $13,269,627 as of December 31, 2024.
• Incurred net losses of $2,170,810 for the six months ended June 30, 2025, and $6,245,737 for the year ended December 31, 2024.
• Used $2,693,714 in cash flows for operating activities during the six months ended June 30, 2025.
• Voting control is highly concentrated in two entities owned by the Chairman and CEO, limiting influence for other investors.
• The equity line of credit with Streeterville Capital, LLC, involves potential dilution for existing shareholders as shares may be sold at a discount to VWAP.
• The company is exposed to additional risks due to reliance on non-employee consultants for executive leadership, including potential misalignment of interests and leadership instability.
• Terminated Chief Marketing Officer and Chief Commercial Officer as part of corporate restructuring, which may adversely impact operational functions.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses, limited revenue, and limited working capital.
• Inability to achieve or maintain profitability in the future, given a history of net losses since inception.
• Failure to effectively manage future growth or evaluate future prospects, especially with expansion into new product categories and global markets.
• Need for additional capital to conduct operations and develop products, with no assurance of obtaining necessary funding on favorable terms or at all.
• Loss of key personnel or inability to attract and retain qualified personnel, particularly in executive leadership, capital markets, M&A, regulatory oversight, and financial structuring.
• Acquisition strategy exposes the company to significant risks, including difficulties in integration, diversion of management attention, unanticipated costs, and failure to realize anticipated benefits.
• Diversification strategy may increase exposure to risks across multiple industries, requiring substantial resources and expertise to manage.
• Inability to finance future acquisitions or expansions, potentially leading to dilution for stockholders or restrictive debt covenants.
• The manufacturing sector, where acquired companies operate, is cyclical and sensitive to economic conditions, raw material costs, and supply chain disruptions.
• Future sales of common stock by selling shareholders, or the perception of such sales, could depress the stock price and impair future capital raising.
• Issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to existing stockholders.
• The company's management team will have broad discretion over the use of proceeds from the equity purchase facility, which may not be invested successfully.

Future Outlook

The company intends to focus on growing revenue through PMGC Capital by acquiring and managing undervalued assets, public and private investments, and structured financing opportunities. It plans to establish new wholly-owned subsidiaries for newly acquired or licensed biotechnology assets, utilize clinical validation studies, and advance EL-22 and EL-32 towards Investigational New Drug (IND) applications. The company will also pursue additional acquisitions of operating companies and biotechnology assets and evaluate potential spin-offs of subsidiaries to unlock shareholder value. The ability to proceed with human trials for EL-22 is contingent upon FDA clearance of the IND submission.

Management Comments

• Management believes the skincare asset divestiture enables dedication of more resources and time to advancing initiatives and assets in larger markets with unmet needs, creating greater growth opportunities.
• The strategic shift positions the company to actively explore and execute potential business acquisitions and high-value biotechnology assets, strengthening the portfolio and driving long-term growth.
• Management believes EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass, based on preclinical data and the myostatin-activin signaling pathway effect.
• Management believes the urgent unmet medical need for muscle preservation during weight loss could be addressed by both EL-22 and EL-32, potentially increasing fat loss for older patients on GLP-1 drugs.
• Management believes EL-22 and EL-32, as oral myostatin formulations, would be early movers in the GLP-1 combination space for muscle preservation, offering convenience over injectable forms.
• Management believes there is opportunity to augment growth for AGA Precision Systems LLC via more proactive business development, targeted outreach in aerospace/defense programs, and participation in trade or industry events.

Industry Context

The company's strategic shift positions it within the rapidly growing global biotechnology market, valued at approximately $1.37 trillion in 2022 and projected to grow at a 12.8% CAGR from 2023 to 2030. A significant focus is on the anti-obesity drug market, which Goldman Sachs predicts could reach $100 billion by 2030. This market is currently dominated by GLP-1 receptor agonists like Ozempic and Mounjaro, which, while effective for weight loss, are associated with significant lean muscle loss (up to 40%). PMGC's EL-22 and EL-32 aim to address this unmet need for muscle preservation, offering a potentially differentiated oral administration method. The company's acquisitions in specialty packaging (Pacific Sun Packaging) and precision machining (AGA Precision Systems) also place it in competitive manufacturing sectors, with AGA benefiting from trends like increased demand for high-precision components and reshoring in aerospace and defense.

Comparison to Industry Standards

• Northstrive Biosciences' EL-22 and EL-32 are positioned to compete in the obesity treatment market, specifically addressing muscle wasting associated with GLP-1 receptor agonists. Key competitors in this space include Novo Nordisk (Ozempic, Wegovy), Eli Lilly (Mounjaro, bimagrumab via Versanis Bio acquisition), Pfizer (danuglipron), Biohaven (taldefgrobep), Scholar Rock (apitegromab), and Veru (enobosarm).
• EL-22 and EL-32 differentiate themselves by leveraging a first-in-class engineered probiotic approach and aiming for oral administration, which is noted as a patient preference over existing injectable GLP-1 and complementary muscle preservation therapies.
• Pacific Sun Packaging operates in the highly competitive packaging industry, differentiating itself through specialization in component-level IT hardware packaging, custom engineering capabilities, U.S.-based operations, and an established customer base of over 300 commercial clients.
• AGA Precision Systems competes in the precision machining and specialty metals CNC market, distinguishing itself through expertise in machining hard and exotic metals (titanium, Inconel) to high tolerances, mold manufacturing capability, and long-standing relationships in aerospace, defense, and industrial sectors.

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing dispute that arose in the normal course of business as of December 31, 2024, was settled in February 2025 to avoid litigation costs. The terms are confidential, but amounts payable were included in accounts payable and accrued liabilities as of December 31, 2024, and paid in full by June 30, 2025.

Related Party Transactions

• The company incurred consulting fees of $391,333 in 2024 and $110,000 in 2023 to GB Capital Ltd, wholly owned by CEO Graydon Bensler. From January 1, 2025, to the prospectus date, $218,332.60 in consulting fees were paid, with $158,400 due in bonus payments and $150,000 paid in bonus payments.
• The company incurred consulting fees of $365,900 in 2024 and $120,000 in 2023 to Northstrive Companies Inc., wholly owned by Chairman Braeden Lichti. From January 1, 2025, to the prospectus date, $274,000 in consulting fees were paid, with $158,400 due in bonus payments and $150,000 paid in bonus payments.
• Secondment Agreement with GB Capital Ltd (wholly owned by Graydon Bensler) on July 25, 2025, for exclusive employee services, with the company reimbursing GB Capital monthly based on agreed hourly rates and extraordinary expenses.
• Secondment Agreement with Northstrive Companies Inc. (wholly owned by Braeden Lichti) on May 7, 2025, for exclusive employee services, with the company reimbursing Northstrive monthly based on agreed hourly rates and extraordinary expenses.
• Amendment No. 3 to consulting agreements for both GB Capital Ltd and Northstrive Companies Inc. on August 12, 2025, providing for 'Acquisition Awards' (RSUs, restricted stock, or cash) based on a percentage of acquisition value (5% to 8%, plus potential 1% discretionary bonus).
• On March 26, 2025, 3,036,437 shares of Series B Preferred Stock were issued to GB Capital Ltd and 3,336,437 shares to Northstrive Companies Inc. as signing bonuses, totaling $150,000, which were accrued as of December 31, 2024.
• An Unsecured Revolving Line of Credit Promissory Note for $200,000 was entered into with NorthStrive Fund II LP (owned and controlled by Braeden Lichti) on June 19, 2024, with 20% annual interest. The note was repaid in full, including $40,000 in interest, prior to the prospectus date.
• As of October 15, 2025, voting control is concentrated, with Northstrive Companies Inc. and GB Capital Ltd collectively holding approximately 81.11% of the company's voting capital stock through Series B Preferred Stock.

Stakeholder Impact

• Shareholders face potential dilution from the equity line of credit and future equity issuances, which could depress the stock price.
• Existing shareholders' voting power is significantly diluted due to the concentrated voting control held by entities owned by the Chairman and CEO.
• Employees may experience changes in operational functions due to the termination of the Chief Marketing Officer and Chief Commercial Officer, but the company is expanding its executive leadership team.
• The strategic shift to biotechnology and diversified investments aims to create long-term growth opportunities and enhance shareholder value.
• The company's ability to continue as a going concern is dependent on securing additional funding, which directly impacts all stakeholders.
• The 2025 Equity Incentive Plan aims to attract and retain key personnel, which is crucial for the company's strategic execution.

Next Steps

• File an Investigational New Drug (IND) application with the U.S. FDA for EL-22 in 2025.
• Initiate clinical trials in the U.S. to evaluate EL-22 in combination with GLP-1 receptor agonists for obesity.
• Continue advancing EL-32, a preclinical probiotic, for muscle preservation in obesity treatments.
• Pursue additional acquisitions of operating companies and biotechnology assets to expand and diversify the portfolio.
• Evaluate potential spin-offs of wholly-owned subsidiaries to unlock shareholder value.
• Formalize business development and marketing efforts for AGA Precision Systems LLC to reach new customers.
• Invest in expanded production capacity and efficiency improvements for AGA Precision Systems LLC.

Key Dates

Recommendation

PMGC Holdings is undergoing a significant strategic transformation, divesting its skincare business to focus on high-growth biotechnology and diversified investments. While the company has successfully raised substantial capital recently through various equity and warrant transactions, and has made strategic acquisitions, it continues to report recurring net losses and carries a significant accumulated deficit, leading to substantial doubt about its ability to continue as a going concern. The concentrated voting control by key executives also presents a governance risk. The potential of its EL-22 and EL-32 biotech assets in the large obesity market is promising, especially with an oral administration advantage, but these are still in early development stages (Phase 1 completed, IND submission planned). Given the high-risk, high-reward nature of its new strategy, coupled with ongoing financial challenges and potential dilution, a 'Hold' recommendation is appropriate for investors who are already exposed and are willing to monitor the execution of the new strategy and clinical development milestones. New investors should approach with extreme caution due to the inherent risks.

Keywords

Biotechnology, SEC Filing, S-1 Registration, Equity Line of Credit, Acquisitions, Biopharmaceutical, Obesity Treatment, Muscle Preservation, GLP-1 Agonists, Specialty Packaging, CNC Machining, Diversified Holdings, Going Concern, Dilution, EL-22, EL-32, Nasdaq